MILLIKELVIN TECHNOLOGIES, LLC — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Elevated levels of glycolysis are known to correlate
MILLIKELVIN TECHNOLOGIES, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $213,347
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA14-071
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
DESCRIPTION (provided by applicant): Elevated levels of glycolysis are known to correlate with the presence and disease stage of various cancers. This phenomenon, known as the Warburg effect, provides the biological basis of Fluoro-Deoxyglucose Positron Emission Tomography (FDG PET) studies. FDG is taken up by the cell in a manner similar to glucose but then remains trapped in the cell for times exceeding an hour. If the 19F atom in the FDG molecule has been irradiated to 18F it can then detected and spatially located using the tomography device. Radioactive 18FDG PET has been shown to be able to spatially locate tumors on length scales down to approximately 8 mm in clinically available devices and has been widely used in the detection and staging of tumorsfor more than 30 years. However, it imposes a non-trivial radioactive burden on the patient; for this reason, 18FDG FDG PET scans for humans are typically limited to not more than once per 12 months per patient and only after a tissue diagnosis has al